BlossomHill Therapeutics, Inc. Cash and Restricted Cash
BlossomHill Therapeutics, Inc. (BLSM) had Cash and Restricted Cash of $95.38 million as of 2026-06-30, per its 10-Q filed 2026-09-18.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-09-18
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $95.38M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $136.68M.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $79.11M.
- 2024-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $100.15M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $95.38M 10-Q · filed 2026-09-18 |
| 2025-12-31 | $136.68M 10-Q · filed 2026-09-18 |
| 2025-06-30 | $79.11M 10-Q · filed 2026-09-18 |
| 2024-12-31 | $100.15M 10-Q · filed 2026-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |